BIOINVENT INTERN. SK 2
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more
Market Cap & Net Worth: BIOINVENT INTERN. SK 2 (BIX0)
BIOINVENT INTERN. SK 2 (F:BIX0) has a market capitalization of $144.21 Million (€140.49 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #19854 globally and #2117 in its home market, demonstrating a 4.91% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOINVENT INTERN. SK 2's stock price €2.14 by its total outstanding shares 65804362 (65.80 Million).
BIOINVENT INTERN. SK 2 Market Cap History: 2015 to 2026
BIOINVENT INTERN. SK 2's market capitalization history from 2015 to 2026. Data shows change from $645.41 Million to $144.21 Million (-9.72% CAGR).
BIOINVENT INTERN. SK 2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOINVENT INTERN. SK 2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BIX0 by Market Capitalization
Companies near BIOINVENT INTERN. SK 2 in the global market cap rankings as of March 19, 2026.
Key companies related to BIOINVENT INTERN. SK 2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BIOINVENT INTERN. SK 2 Historical Marketcap From 2015 to 2026
Between 2015 and today, BIOINVENT INTERN. SK 2's market cap moved from $645.41 Million to $ 144.21 Million, with a yearly change of -9.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €144.21 Million | -21.51% |
| 2025 | €183.73 Million | -18.07% |
| 2024 | €224.25 Million | +97.38% |
| 2023 | €113.61 Million | -39.82% |
| 2022 | €188.79 Million | -36.36% |
| 2021 | €296.66 Million | -5.83% |
| 2020 | €315.04 Million | +150.42% |
| 2019 | €125.81 Million | -48.41% |
| 2018 | €243.84 Million | -16.53% |
| 2017 | €292.14 Million | -39.30% |
| 2016 | €481.27 Million | -25.43% |
| 2015 | €645.41 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of BIOINVENT INTERN. SK 2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $144.21 Million USD |
| MoneyControl | $144.21 Million USD |
| MarketWatch | $144.21 Million USD |
| marketcap.company | $144.21 Million USD |
| Reuters | $144.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.